Merck Net Change in Property, Plant, and Equipment 2010-2025 | MRK
Merck annual/quarterly net change in property, plant, and equipment history and growth rate from 2010 to 2025. Net change in property, plant, and equipment can be defined as the overall change in capital expenditures and sales of plant, property and equipment. This field is used if a company does not report separately sales and purchases of plant, property and equipment or is calculated as the sum of purchases and sales of PP&E
- Merck net change in property, plant, and equipment for the quarter ending March 31, 2025 was $-3.372B, a 12.71% decline year-over-year.
- Merck net change in property, plant, and equipment for the twelve months ending March 31, 2025 was $-8.320B, a 14.37% decline year-over-year.
- Merck annual net change in property, plant, and equipment for 2024 was $-3.372B, a 12.71% decline from 2023.
- Merck annual net change in property, plant, and equipment for 2023 was $-3.863B, a 11.96% decline from 2022.
- Merck annual net change in property, plant, and equipment for 2022 was $-4.388B, a 1.35% decline from 2021.
Merck Annual Net Change in Property, Plant, and Equipment
(Millions of US $) |
| 2024 |
$-3,372 |
| 2023 |
$-3,863 |
| 2022 |
$-4,388 |
| 2021 |
$-4,448 |
| 2020 |
$-4,429 |
| 2019 |
$-3,369 |
| 2018 |
$-2,615 |
| 2017 |
$-1,888 |
| 2016 |
$-1,614 |
| 2015 |
$-1,283 |
| 2014 |
$-1,317 |
| 2013 |
$-1,548 |
| 2012 |
$-1,954 |
| 2011 |
$-1,723 |
| 2010 |
$-1,678 |
| 2009 |
$-1,461 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$196.697B |
$64.168B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
